OncoGenex Cash To Last Into 2010

Xconomy Seattle — 

OncoGenex Pharmaceuticals, the Bothell, WA-based developer of cancer drugs, said today it had $12.4 million in cash and investments left at the end of 2008, which ought to be enough to fund its operations through February 2010. OncoGenex (NASDAQ: OGXI) hopes to use the cash to further develop its experimental prostate cancer drug which showed in a clinical trial in December that it helped patients live about 10 months longer than if they got chemotherapy alone.